🌹 Brimonidine & Oxymetazoline Vasoconstriction Simulator

Alpha-Adrenoreceptor Binding on Facial Vessels

Placeholder: agonists dock onto alpha-1 and alpha-2 receptors on vessel walls.

• α1/α2: Target receptor (Placeholder subtype note)
• α2-selective: Brimonidine affinity (Placeholder affinity note)
• α1-selective: Oxymetazoline affinity (Placeholder affinity note)
• Minutes: Onset (Placeholder onset note)

Receptor pharmacology basics

Placeholder: short note on receptor subtype binding kinetics.

Rapid Smooth-Muscle Vasoconstriction

Placeholder: receptor activation triggers vessel wall smooth muscle contraction.

• ~5-15 min: Onset speed (Placeholder speed note)
• 1-3 hrs: Peak effect (Placeholder peak note)
• ↓ sharply: Vessel diameter (Placeholder diameter note)
• Gi/Gq signaling: Mechanism (Placeholder mechanism note)

Signaling to contraction

Placeholder: brief note on second-messenger contraction cascade.

Temporary Reduction of Visible Facial Redness

Placeholder: reduced blood flow lowers visible redness for several hours.

• ~6 hrs: Duration (brimonidine) (Placeholder duration note)
• ~12 hrs: Duration (oxymetazoline) (Placeholder duration note)
• Cosmetic only: Redness masked (Placeholder scope note)
• Rosacea erythema: Common use (Placeholder use note)

Duration of visible effect

Placeholder: short note on how long redness stays reduced.

Wear-off and Rebound Flushing Risk

Placeholder: as drug clears, vessels can dilate beyond baseline redness.

• Late hours: Rebound window (Placeholder window note)
• Receptor downregulation: Risk driver (Placeholder driver note)
• Variable: Severity (Placeholder severity note)
• Limit frequency: Mitigation (Placeholder mitigation note)

Why rebound happens

Placeholder: short note on tachyphylaxis and rebound vasodilation.

Cosmetic Masking vs Disease-Modifying Treatment

Placeholder: these agents mask symptoms, not the underlying rosacea process.

• No: Disease-modifying? (Placeholder distinction note)
• Unaddressed: Underlying cause (Placeholder cause note)
• Anti-inflammatory tx: Complementary care (Placeholder care note)
• Temporary effect: Patient expectation (Placeholder expectation note)

Setting realistic expectations

Placeholder: short note distinguishing symptom relief from cure.

Placeholder: these drugs treat appearance, not rosacea pathology.